-
Je něco špatně v tomto záznamu ?
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries
H. Leblebicioglu, JE. Arends, R. Ozaras, G. Corti, L. Santos, C. Boesecke, A. Ustianowski, AS. Duberg, S. Ruta, NN. Salkic, P. Husa, I. Lazarevic, JA. Pineda, NY. Pshenichnaya, T. Tsertswadze, M. Matičič, E. Puca, G. Abuova, J. Gervain, R....
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- antivirové látky terapeutické užití MeSH
- elastografie MeSH
- Hepacivirus * MeSH
- hepatitida C diagnóza farmakoterapie epidemiologie virologie MeSH
- lidé MeSH
- prevalence MeSH
- úhrada zdravotního pojištění MeSH
- virová nálož MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Asie epidemiologie MeSH
- Evropa epidemiologie MeSH
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. RESULTS: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (≤1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. CONCLUSION: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre Ljubljana Slovenia
Department of Gastroenterology University Hospital of Heraklion Heraklion Crete Greece
Department of Infection Diseases University Hospital Center Tirane Albania
Department of Medicine 1 Bonn University Bonn Germany
Faculty of Medicine Ivane Javakhishvili Tbilisi State University Tbilisi Georgia
Infectious Disease Unit University of Florence School of Medicine Florence Italy
Infectious Diseases AIDS and Clinical Immunology Research Center Tbilisi Georgia
Infectious Diseases Department South Kazakhstan State Pharmaceutical Academy Shymkent Kazakhstan
Infectious Diseases Hôpitaux Universitaires Paris Centre Université Paris Descartes Paris France
Institute of Microbiology and Immunology Faculty of Medicine University of Belgrade Belgrade Serbia
Masaryk University Infectious Diseases Brno Czech Republic
Rostov State Medical University Rostov on Don Russia
University Hospital Brno Infectious Diseases Brno Czech Republic
University Hospital of Infectious Diseases Zagreb School of Medicine Zagreb Croatia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024445
- 003
- CZ-PrNML
- 005
- 20180712091044.0
- 007
- ta
- 008
- 180709s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.antiviral.2017.12.001 $2 doi
- 035 __
- $a (PubMed)29217468
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Leblebicioglu, Hakan $u Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University, Medical School, Samsun, Turkey. Electronic address: hakanomu@yahoo.com.
- 245 10
- $a Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries / $c H. Leblebicioglu, JE. Arends, R. Ozaras, G. Corti, L. Santos, C. Boesecke, A. Ustianowski, AS. Duberg, S. Ruta, NN. Salkic, P. Husa, I. Lazarevic, JA. Pineda, NY. Pshenichnaya, T. Tsertswadze, M. Matičič, E. Puca, G. Abuova, J. Gervain, R. Bayramli, S. Ahmeti, M. Koulentaki, B. Kilani, A. Vince, F. Negro, M. Sunbul, D. Salmon, . ,
- 520 9_
- $a BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. RESULTS: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (≤1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. CONCLUSION: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
- 650 _2
- $a antivirové látky $x terapeutické užití $7 D000998
- 650 _2
- $a Asie $x epidemiologie $7 D001208
- 650 _2
- $a elastografie $7 D054459
- 650 _2
- $a Evropa $x epidemiologie $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a Hepacivirus $7 D016174
- 650 _2
- $a hepatitida C $x diagnóza $x farmakoterapie $x epidemiologie $x virologie $7 D006526
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a úhrada zdravotního pojištění $7 D007349
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a virová nálož $7 D019562
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Arends, Joop E $u Internal Medicine and Infectious Diseases, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Ozaras, Resat $u Department of Infectious Diseases and Clinical Microbiology, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey.
- 700 1_
- $a Corti, Giampaolo $u Infectious Disease Unit, University of Florence School of Medicine, Florence, Italy.
- 700 1_
- $a Santos, Lurdes $u Infectious Diseases Service C Hospitalar São João, Faculty of Medicine, Alameda Professor Hernani Monteiro, Porto, Portugal.
- 700 1_
- $a Boesecke, Christoph $u Department of Medicine I, Bonn University, Bonn, Germany.
- 700 1_
- $a Ustianowski, Andrew $u Infectious Diseases & Tropical Medicine and Research Lead, North Western Infectious Diseases Unit, Pennine Acute Hospitals NHS Trust, North Manchester General Hospital, Delaunays Road, Manchester, UK.
- 700 1_
- $a Duberg, Ann-Sofi $u Department of Infectious Diseases, Örebro University Hospital, School of Medical Sciences, Örebro, Sweden.
- 700 1_
- $a Ruta, Simona $u Carol Davila University of Medicine and Pharmacy, Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
- 700 1_
- $a Salkic, Nermin N $u Department of Gastroenterology and Hepatology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
- 700 1_
- $a Husa, Petr $u Masaryk University, Infectious Diseases, Brno, Czech Republic; University Hospital Brno, Infectious Diseases, Brno, Czech Republic.
- 700 1_
- $a Lazarevic, Ivana $u Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- 700 1_
- $a Pineda, Juan A $u Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avda. de Bellavista, Sevilla, Spain.
- 700 1_
- $a Pshenichnaya, Natalia Yurievna $u Rostov State Medical University, Rostov-on-Don, Russia.
- 700 1_
- $a Tsertswadze, Tengiz $u Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia; Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia.
- 700 1_
- $a Matičič, Mojca $u Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia.
- 700 1_
- $a Puca, Edmond $u Department of Infection Diseases, University Hospital Center, Tirane, Albania.
- 700 1_
- $a Abuova, Gulzhan $u Infectious Diseases Department, South - Kazakhstan State Pharmaceutical Academy, Shymkent, Kazakhstan.
- 700 1_
- $a Gervain, Judit $u Division Hepato-Pancreatology 1st Department of Gastroenterology and Molecular Diagnostic Laboratory, "Szent György" Teaching Hospital Székesfehérvár, Hungary.
- 700 1_
- $a Bayramli, Ramin $u Department of Microbiology and Immunology, Azerbaijan Medical University, Educational Therapeutic Hospital, Baku, Azerbaijan.
- 700 1_
- $a Ahmeti, Salih $u Infectious Disease Clinic, University Clinical Centre of Kosova, Faculty of Medicine, Prishtina University, Pristina, Kosovo.
- 700 1_
- $a Koulentaki, Mairi $u Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Crete, Greece.
- 700 1_
- $a Kilani, Badreddine $u Service des Maladies Infectieuses, Faculté de Médecine de Tunis, Université Tunis EL Manar, Hôpital la Rabta, Tunis, Tunisia.
- 700 1_
- $a Vince, Adriana $u University Hospital of Infectious Diseases, Zagreb School of Medicine, Zagreb, Croatia.
- 700 1_
- $a Negro, Francesco $u Divisions of Gastroenterology and Hepatology of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland.
- 700 1_
- $a Sunbul, Mustafa $u Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University, Medical School, Samsun, Turkey.
- 700 1_
- $a Salmon, Dominique $u Infectious Diseases, Hôpitaux Universitaires Paris Centre, Université Paris Descartes, Paris, France.
- 700 1_
- $a ,
- 773 0_
- $w MED00000480 $t Antiviral research $x 1872-9096 $g Roč. 150, č. - (2018), s. 9-14
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29217468 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712091336 $b ABA008
- 999 __
- $a ok $b bmc $g 1316576 $s 1021366
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 150 $c - $d 9-14 $e 20171205 $i 1872-9096 $m Antiviral research $n Antiviral Res $x MED00000480
- LZP __
- $a Pubmed-20180709
